Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
|Articles|February 1, 1995
- ONCOLOGY Vol 9 No 2
- Volume 9
- Issue 2
Cancer Drugs Under Development
According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.
Advertisement
According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.
Articles in this issue
almost 32 years ago
Early Results of RTOG Small-Cell Lung Cancer Trialalmost 32 years ago
The Economics of Oncology: Health System Reform and Clinical Researchalmost 32 years ago
An Update on the Pros and Cons of Preventive Mastectomyalmost 32 years ago
The Effect of Tamoxifen on the Endometriumalmost 32 years ago
Commentary (Look): The Effect of Tamoxifen on the Endometriumalmost 32 years ago
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometriumalmost 32 years ago
Management of Papillary Thyroid Canceralmost 32 years ago
Commentary (Cady): Management of Papillary Thyroid Canceralmost 32 years ago
The Management of Early Ovarian CancerAdvertisement
Related to this article
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Advertisement
Advertisement
Trending on CancerNetwork
1
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
2
Closing the Gaps in Precision Oncology for Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5